Cathelicidins-Therapeutic antimicrobial and antitumor host defense peptides for oral diseases

Japanese Dental Science Review

Volumn 47, Issue 1, 2011, Pages 67-81

  Okumura, Kazuhiko ^a  

^a HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

Cathelicidin peptide; Host defense peptide; Oral lichen planus; Oral mucositis; Oral squamous cell carcinoma; Periodontal disease

Indexed keywords

EID: 78751567920     PISSN: 18827616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdsr.2010.11.001     Document Type: Review

References (151)

1. Presland R.B., Dale B.A. Epithelial structural protein of the skin and oral cavity: function in health and disease. Crit Rev Oral Biol Med 2000, 11:383-408.
2. Abiko Y., Saitoh M., Nishimura M., Yamazaki M., Sawamura D., Kaku T. Role of β-defensins in oral epithelial health and disease. Med Mol Morphol 2007, 40:179-184.
3. De Smet K., Contreas R. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett 2005, 27:1337-1347.
4. Murakami M., Ohtake T., Dorschner R.A., Schittek B., Grabe C., Gallo R.L. Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J Invest Dermatol 2002, 119:1090-1095.
5. Epand R.M., Vogel H.J. Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta 1999, 1462:11-28.
6. Boman H.G. Peptide antibiotics and their role in innate immunity. Annu Rev Immunol 1995, 13:61-92.
7. Selsted M.E., Miller S.I., Henschen A.H., Ouellene A.J. Enteric defensins: antibiotic peptide components of intestinal host defense. J Cell Biol 1992, 118:929-936.
8. Jones D.E., Bevins C.L. Defensin-6 mRNA in human paneth cells: implications for antimicrobial peptides in host defense of the human bowel. FEBS Lett 1993, 315:187-192.
9. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003, 3:710-720.
10. Schutte B.C., Mitros J.P., Bartlett J.A., Walters J.D., Jia H.P., Welsh M.J., Casavant T.L., McCray P.B. Discovery of five conserved β-defensin gene clusters using a computational search strategy. Proc Natl Acad Sci U S A 2002, 99:2129-2133.
11. Tang Y.Q., Yuan J., Osapay G., Osapay K., Tran D., Miller C.J., Ouellette A.J., Selsted M.E. A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated α-defensins. Science 1999, 286:498-502.
12. Nakamura T., Furunaka H., Miyata T., Tokunaga F., Muta T., Iwanaga S., Niwa M., Takao T., Shimonishi Y. Tachyplesin, a class of antimicrobial peptide from the hemocytes of the horseshoe crab (Tachypleus tridentatus). Isolation and chemical structure. J Biol Chem 1988, 263:16709-16713.
13. Kokryakov V.N., Harwig S.S., Panyutich E.A., Shevchenko A.A., Aleshina G.M., Shamova O.V., Korneva H.A., Lehrer R.I. Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins. FEBS Lett 1993, 327:231-236.
14. Agerberth B., Gunne H., Oderberg J., Kogner P., Boman H.G., Gudmundsson G.H. FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc Natl Acad Sci U S A 1995, 92:195-199.
15. Cowland J.B., Johnsen A.H., Borregaard N. hCAP-18, a cathelin/pro-bacternecin-like protein of human neutrophil specific granules. FEBS Lett 1995, 368:173-176.
16. Larrick J.W., Lee J., Ma S., Li X., Francke U., Wright S.C., Balint R.F. Structural, functional analysis and localization of human CAP18 gene. FEBS Lett 1996, 398:74-80.
17. Skerlavaj B., Gennaro R., Bagella L., Merluzzi L., Risso A., Zanetti M. Biological characterization of two novel cathelicidin-derived peptides and identification of structural requirements for their antimicrobial and cell lytic activities. J Biol Chem 1996, 271:28375-28381.
18. Steiner H., Hultmark D., Engström A., Bennich H., Boman H.G. Sequence and specificity of two antibacterial proteins involved in insect immunity. Nature 1981, 292:246-248.
19. Hultmark D., Engström A., Bennich H., Kapur R., Boman H.G. Insect immunity: isolation and structure of cecropin D and four minor antibacterial components from Cecropia pupae. Eur J Biochem 1982, 127:207-217.
20. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci U S A 1987, 84:5449-5453.
21. Amiche M., Seon A.A., Pierre T.N., Nicolas P. The dermaseptin precursors: a protein family with a common preproregion and a variable C-terminal antimicrobial domain. FEBS Lett 1999, 456:352-356.
22. Park C.B., Kim M.S., Kim S.C. A novel antimicrobial peptide from Bufo bufo gargarizans. Biochem Biophys Res Commun 1996, 218:408-413.
23. Romeo D., Skerlavaj B., Bolognesi M., Gennaro R. Structure and bactericidal activity of an antibiotic dodecapeptide purified from bovine neutrophils. J Biol Chem 1988, 263:9573-9575.
24. Fehlbaum P., Bulet P., Chernysh S., Briand J.P., Roussel J.P., Letellier L., Hetru C., Hoffmann J.A. Structure-activity analysis of thanatin, a 21-residue inducible insect defense peptide with sequence homology to frog skin antimicrobial peptides. Proc Natl Acad Sci U S A 1996, 93:1221-1225.
25. Morikawa M., Hagiwara K., Nakajima T. Brevinin-1 and -2, unique antimicrobial peptides from the skin of the frog, Rana brevipoda porsa. Biochem Biophys Res Commun 1992, 189:184-190.
26. Simmaco M., Mignogna G., Barra D., Bossa F. Novel antimicrobial peptides from skin secretion of the European frog Rana esculenta. FEBS Lett 1993, 324:159-161.
27. Gennaro R., Skerlavaj B., Romeo D. Purification, composition, and activity of two bactenecins, antibacterial peptides of bovine neutrophils. Infect Immun 1989, 57:3142-3146.
28. Storici P., Zanetti M. A cDNA derived from pig bone marrow cells predicts a sequence identical to the intestinal antibacterial peptide PR-39. Biochem Biophys Res Commun 1993, 196:1058-1065.
29. Selsted M.E., Novotny M.J., Morris W.L., Tang Y.Q., Smith W., Cullor J.S. Indolicidin, a novel bactericidal tridecapeptide amide from neutrophils. J Biol Chem 1992, 267:4292-4295.
30. Castagnola M., Inzitari R., Rossetti D.V., Olmi C., Cabras T., Piras V., Nicolussi P., Sanna M.T., Pellegrini M., Giardina B., Messana I. A cascade of 24 histatins (histatin 3 fragments) in human saliva. Suggestions for a pre-secretory sequential cleavage pathway. J Biol Chem 2004, 279:41436-41443.
31. Cole A.M., Hong T., Boo L.M., Nguyen T., Zhao C., Bristol G., Zack J.A., Waring A.J., Yang O.O., Lehrer R.I. Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci U S A 2002, 99:1813-1818.
32. Lehrer R.I., Ganz T. Cathelicidins: a family of endogenous antimicrobial peptides. Curr Opin Hematol 2002, 9:18-222.
33. Zannetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 2004, 75:39-48.
34. Turner J., Cho Y., Dinh N.N., Waring A.J., Lehrer R.I. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 1998, 42:2206-2214.
35. MacKay B.J., Pollock J.J., Iacono V.J., Baum B.J. Isolation of milligram quantities of a group of histidine-rich polypeptides from human parotid saliva. Infect Immun 1984, 44:688-694.
36. Sabatini L.M., Azen E.A. Histatins, a family of salivary histidine-rich proteins, are encoded by at least two loci (HIS1 and HIS2). Biochem Biophys Res Commun 1989, 160:495-502.
37. Oppenheim F.G., Xu T., McMillian F.M., Levitz S.M., Diamond R.D., Offner G.D., Troxler R.F. Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J Biol Chem 1988, 263:7472-7477.
38. Dürr U.H.N., Sudheendra U.S., Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta 2006, 1758:1408-1425.
39. Johansson J., Gudmundsson G.H., Rottenberg M.E., Berndt K.D., Agerberth B. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J Biol Chem 1998, 273:3718-3724.
40. Sørensen O.E., Follin P., Johnsen A.H., Calafat J., Tjabringa G.S., Hiemstra P.S., et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 2001, 97:3951-3959.
41. Yamasaki K., Schauber J., Coda A., Lin H., Dorschner R.A., Schechter N.M., Bonnart C., Descargues P., Hovnanian A., Gallo R.L. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 2006, 20:2068-2080.
42. Sørensen O.E., Gram L., Johnsen A.H., Andersson E., Bangsbøll S., et al. Processing of seminal plasma hCAP-18 to ALL-38 by gastricsin: a novel mechanism of generating antimicrobial peptides in vagina. J Biol Chem 2003, 278:28540-28546.
43. Weiss J., Olsson I. Cellular and subcellular localization of the bacterial/permeability-increasing protein of neutrophils. Blood 1987, 69:652-659.
44. Ganz T., Selsted M.E., Szklarek D., Harwing S.S.L., Daher K., Bainton D.F., et al. Defensins: natural peptide antibiotics of human neutrophils. J Clin Invest 1985, 76:1427-1435.
45. Campanelli D., Detmers P.A., Nathan C.F., Gabay J.E. Azurocidin and a homologous serine protease from neutrophils: differential antimicrobial and proteolytic properties. J Clin Invest 1990, 85:904-915.
46. Sørensen O.E., Arnlijots K., Cowkland J.B., Bainton D.F., Borregaard N. The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood 1997, 90:2796-2803.
47. Agerberth B., Charo J., Werr J., Olsson B., Idali F., Lindbom L., et al. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000, 96:3086-3093.
48. Di Nardo A., Vitiello A., Gallo R.L. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol 2003, 170:2274-2278.
49. Nilsson M.F., Sandstedt B., Sørensen O., Weber G., Borregaard N., Ståhle-Bäckdahl M. The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. Infect Immun 1999, 67:2561-2566.
50. Bals R., Wang X., Zasloff M., Wilson J.M. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci U S A 1998, 95:9541-9546.
51. Hase K., Eckmann L., Leopard J.D., Varki N., Kagnoff M.F. Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium. Infect Immun 2002, 70:953-963.
52. Murakami M., Ohtake T., Dorschner R.A., Gallo R.L. Cathelicidin antimicrobial peptides are expressed in salivary glands and saliva. J Dent Res 2002, 81:845-850.
53. Bals R., Wilson J.M. Cathelicidins-a family of multifunctional antimicrobial peptides. Cell Mol Life Sci 2003, 60:711-720.
54. Armogida S., Yannaras N.M., Melton A., Srivastava M. Identification and quantification of innate immune system mediators in human breast milk. Allergy Asthma Proc 2004, 25:297-304.
55. Frohm M., Agerberth B., Ahangari G., Stâhle-Bäckdahl M., Lidén S., Wigzell H., Gudmundsson G.H. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem 1997, 272:15258-15263.
56. Dorschner R.A., Pestonjamasp V.K., Tamakuwala S., Ohtake T., Rudisill J., Nizet V., Agerberth B., Gudmundsson G.H., Gallo R.L. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol 2001, 117:91-97.
57. Braff M.H., Di Nardo A., Gallo R.L. Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. J Invest Dermatol 2005, 124:394-400.
58. Boman H.G., Agerberth B., Boman A. Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine. Infect Immun 1993, 61:2978-2984.
59. Huang H.W. Action of antimicrobial peptides: two-state model. Biochemistry 2000, 39:8347-8352.
60. Brogden K.A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. Nat Rev Microbiol 2005, 3:238-250.
61. Tanaka D., Miyasaki K.T., Lehrer R.I. Sensitivity of Actinobacillus actinomycetemcomitans and Capnocytophaga spp. to the bactericidal action of LL-37: a cathelicidin found in human leukocytes and epithelium. Oral Microbiol Immunol 2000, 15:226-231.
62. Isogai E., Isogai H., Matuo K., Hirose K., Kowashi Y., Okumura K., et al. Sensitivity of genera Porphyromonas and Prevotella to the bactericidal action of C-terminal domain of human CAP18 and its analogues. Oral Microbiol Immunol 2003, 18:329-332.
63. Ouhara K., Komatsuzawa H., Yamada S., Shiba H., Fujiwara T., Ohara M., et al. Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides. β-defensins and LL37, produced by human epithelial cells. J Antimicrob Chemother 2005, 55:888-896.
64. Isogai E., Hirata M., Isogai H., Matui K., kimura K., Yokota K., et al. Antimicrobial activity of synthetic human CAP18 peptides to Streptococcus sanguis isolated from patients with Behçet's disease. Adv Exp Med Biol 2003, 528:195-200.
65. Nagaoka I., Hirota S., Yomogida S., Ohwada A., Hirata M. Synergistic actions of antibacterial neutrophil defensins and cathelicidins. Inflamm Res 2000, 49:73-79.
66. Travis S.M., Anderson N.N., Forsyth W.R., Espiritu C., Conway B.D., Greenberg E.P., et al. Bactericidal activity of mammalian cathelicidin-derived peptides. Infect Immun 2000, 68:2748-2755.
67. Izutsu K., Johnson D., Schubert M., Wang E., Ramsey B., Tamarin A., et al. Electron microprobe analysis of human labial gland secretory granules in cystic fibrosis. J Clin Invest 1985, 75:1951-1956.
68. Bals R., Weiner D.J., Meegalla R.L., Wison J.M. Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J Clin Invest 1999, 103:1113-1117.
69. López-García B., Lee P.H.A., Yamasaki K., Gallo R.L. Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection. J Invest Dermatol 2005, 125:108-115.
70. den Hertog A.L., van Marle J., van Veen H.A., Van't Hof W., Bolscher J.G., Veerman E.C., et al. Candidacidal effects of two antimicrobial peptides: histatin 5 causes small membrane defects, but LL-37 causes massive disruption of the cell membrane. Biochem J 2005, 388:689-695.
71. den Hertog A.L., van Marle J., Veerman E.C., Valentijn-Benz M., Nazmi K., Kalay H., et al. The human cathelicidin peptide LL-37 and truncated variants induce segregation of lipids and proteins in the plasma membrane of Candida albicans. Biol Chem 2006, 387:1495-14502.
72. Yashin B., Pang M., Turner J.S., Cho Y., Dinh N.N., Waring A.J., et al. Evaluation of the inactivation of infectious Herpes simplex virus by host-defense peptides. Eur J Clin Microbiol Infect Dis 2000, 19:187-194.
73. Howell M.D., Jones J.F., Kisich K.O., Streib J.E., Gallo R.L., Leung D.Y. Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J Immunol 2004, 172:1763-1767.
74. Gordon Y.J., Huang L.C., Romanowski E.G., Yates K.A., Proske R.J., McDermott A.M. Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr Eye Res 2005, 30:385-394.
75. Krishna R., Mayer L.D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000, 11:265-283.
76. Yeaman M.R., Yount N.Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 2003, 55:27-55.
77. Chan S.C., Yau W.L., Wang W., Smith D.K., Sheu F.S., Chen H.M. Microscopic observations of the different morphological changes caused by anti-bacterial peptides on Klebsiella pneumoniae and HL-60 leukemia cells. J Pept Sci 1998, 4:413-425.
78. Papo N., Shahar M., Eisenbach L., Shai Y. A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and in mice. J Biol Chem 2003, 278:21018-21023.
79. Utsugi T., Schroit A.J., Connor J., Bucana C.D., Fidler I.J. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 1991, 51:3062-3066.
80. Chen H.M., Wang W., Snith D., Chan S.C. Effects of the anti-bacterial peptide cecropin B and its analogs, cecropins B-1 and B-2, on liposomes, bacteria, and cancer cells. Biochim Biophys Acta 1997, 1336:171-179.
81. Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim Biophys Acta 1999, 1462:55-70.
82. Mai J.C., Mi Z., Kim S.H., Ng B., Robbins P.D. A proapoptotic peptide for the treatment of solid tumors. Cancer Res 2001, 61:7709-7712.
83. Cruciani R.A., Barker J.L., Zasloff M., Chen H.C., Colamonici O. Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation. Proc Natl Acad Sci U S A 1991, 88:3792-3796.
84. Merrifiled R.B., Juvvadi P., Andreu D., Ubach J., Boman A., Boman H.G. Retro and retroenantio analogs of cecropin-melittin hybrids. Proc Natl Acad Sci U S A 1995, 92:3449-3453.
85. Hetru C., Letellier L., Oren Z., Hoffmann J.A., Shai Y. Androctonin, a hydrophilic disulphide-bridged non-haemolytic anti-microbial peptide: a plausible mode of action. Biochem J 2000, 345:653-664.
86. Ellerby H.M., Arap W., Ellerby L.M., Kain R., Andrusiak R., Del Rio G. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999, 5:1032-1038.
87. Chen Y., Xu X., Hong S., Chen J., Liu N., Underhill C.B., et al. RGD-Tachyplesin inhibits tumor growth. Cancer Res 2001, 61:2434-2438.
88. Park N.G., Lee S., Oishi O., Aoyagi H., Iwanaga S., Yamashita S., et al. Conformation of tachyplesin I from Tachypleus tridentatus when interacting with lipid matrices. Biochemistry 1992, 31:12241-12247.
89. Risso A., Zanetti M., Gennaro R. Cytotoxicity and apoptosis mediated by two peptides of innate immunity. Cell Immunol 1998, 189:107-115.
90. Risso A., Braidot E., Concetta M., Sordano C., Vianello A., Macri F., et al. BMAP-28, an antibiotic peptide of innate immunity, induces cell death through opening of the mitochondrial permeability transition pore. Mol Cell Biol 2002, 22:1926-1935.
91. Okumura K., Itoh A., Isogai E., Hirose K., Hosokawa Y., Abiko Y., et al. C-terminal domain of human CAP18 antimicrobial peptide induces apoptosis in oral squamous cell carcinoma SAS-H1 cells. Cancer Lett 2004, 212:185-194.
92. Lau Y.E., Bowdish D.M., Cosseau C., Hancock R.E., Davidson D.J. Apoptosis of airway epithelial cells: human serum sensitive induction by the cathelicidin LL-37. Am J Respir Cell Mol Biol 2006, 34:399-409.
93. Barlow P.G., Li Y., Wilkinson T.S., Bowdish D.M., Lau Y.E., Cosseau C., Haslett C., et al. The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system. J Leukoc Biol 2006, 80:509-520.
94. Nagaoka I., Tamura H., Hirata M. An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and P2X7. J Immunol 2006, 176:3044-3052.
95. Mookherjee N., Brown K.L., Bowdish D.M., Doria S., Falsafi R., Hokamp K., et al. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 2006, 176:2455-2464.
96. Galanos C., Freudenberg M.A., Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci U S A 1979, 76:5939-5943.
97. Nagaoka I., hirota S., Niyonsaba F., Hirata M., Adachi Y., Tamura H., et al. Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD14(+) cells. J Immunol 2001, 167:3329-3338.
98. Hirata M., Shimomura Y., Yoshida M., Morgan J.G., Palings I., Wilson D., et al. Characterization of a rabbit cationic protein (CAP18) with lipopolysaccharide-inhibitory activity. Infect Immun 1994, 62:1421-1426.
99. Larrick J.W., Hirata M., Zheng H., Zhong J., Bolin D., Cavaillon J.M., et al. A novel granulocyte-derived peptide with lipopolysaccharide-neutralizing activity. J Immunol 1994, 152:231-240.
100. Scott M.G., Davidson D., Gold M.R., Bowdish D., Hancock R.E. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol 2002, 169:3883-3891.
101. Ohgami K., Ilieva I.B., Shiratori K., Isogai E., Yoshida K., Kotake S., et al. Effect of human cationic antimicrobial protein 18 peptide on endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 2003, 44:4412-4418.
102. Yang D., Chen Q., Schmidt A.P., Anderson G.M., Wang J.M., Wooters J., et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 2000, 192:1069-1074.
103. Niyonsaba F., Iwabuchi K., Someya A., Hirata M., Matsuda H., Ogawa H., et al. A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology 2002, 106:20-26.
104. Tjabringa G.S., Aarbiou J., Ninaber D.K., Drijfhout J.W., Sørensen O.E., Borregaard N., et al. The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J Immunol 2003, 171:6690-6696.
105. 7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J Immunol 2004, 172:4987-4994.
106. Wang T.-T., Nestel F.P., Bourdeau V., Nagai Y., Wang Q., Liao J., et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004, 173:2909-2912.
107. Gombart A.F., Boregaard N., Koeffler H.P. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J 2005, 19:1067-1077.
108. Weber G., Heiborn J.D., Chamorro Jimenez C.I., Hammarsjo A., Törmä H., et al. Vitamin D induces the antimicrobial protein hCAP18 in human skin. J Invest Dermatol 2005, 124:1080-1082.
109. Davidson D.J., Currie A.J., Reid G.S., Bowdish D.M., MacDonald K.L., Ma R.C., et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol 2004, 172:1146-1156.
110. Lande R., Gregorio J., Facchinrtti V., Chatterjee B., Wang Y.H., Homey B., et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007, 449:564-569.
111. Santoro A., Majorana A., Roversi L., Gentili F., Marrelli S., Vermi W., et al. Recruitment of dendritic cells in oral lichen planus. J Pathol 2005, 205:426-434.
112. Kajita K., Honda T., Amanuma R., Domon H., Okui T., Ito H., et al. Quantitative messenger RNA expression of Toll-like receptors and interferon-alpha1 in gingivitis and periodontitis. Oral Microbiol Immunol 2007, 22:398-402.
113. Koczulla R., von Degenfeld G., Kupatt C., Krötz F., Zahler S., Gloe T., et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 2003, 111:1665-1672.
114. Tao R., Jurevic R.J., Coulton K.K., Tsutsui M.T., Roberts M.C., Kimball J.R., et al. Salivary antimicrobial peptide expression and dental caries experience in children. Antimicrob Agents Chemother 2005, 49:3883-3888.
115. Hosokawa I., Hosokawa Y., Komatsuzawa H., Goncalves R.B., Kainbox N., Napimoga M.H., et al. Innate immune peptide LL-37 displays distinct expression pattern from beta-defensins in inflamed gingival tissue. Clin Exp Immunol 2006, 146:218-225.
116. Ji S., Park E., Lee B.-L., Kim K.-K., Choi Y. Susceptibility of various oral bacteria to antimicrobial peptides and to phagocytosis by neutrophils. J Periodont Res 2007, 42:410-419.
117. Pütsep K., Carlsson G., Boman H.G., Andersson M. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet 2002, 360:1144-1149.
118. Carlsson G., Wahlin Y.-B., Johansson A., Olsson A., Eriksson T., Claesson R., et al. Periodontal disease in patients from the original Kostmann family with severe congenital neutropenia. J Periodontol 2006, 77:744-751.
119. Nagaoka I., Hirata M., Sugimoto K., Tsutsumi-Ishii Y., Someya A., Saionji K., et al. Evaluation of the expression of human CAP18 gene during neutrophil maturation in the bone marrow. J Leukoc Biol 1998, 64:845-852.
120. Klein C., Grudzien M., Appaswamy G., Germeshausen M., Sandrock I., Schäffer A.A., et al. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet 2007, 39:86-92.
121. de Haar S.F., Hiemstra P.S., van Steenbergen M.T., Everts V., Beertsen W. Role of polymorphonuclear leukocyte-derived serine proteinases in defense against Actinobacillus actinomycetemcomitans. Infect Immun 2006, 74:5284-5291.
122. Abiko Y., Jinbu Y., Noguchi T., Nisimura M., Kusano K., Amaratunga P., et al. Upregulation of human beta-defensin 2 peptide expression in oral lichen planus, leukoplakia and candidiasis. An immunohistochemical study. Pathol Res Pract 2002, 198:537-542.
123. Sørensen O.E., Cowland J.B., Theilgaard-Mönch K., Liu L., Ganz T., Borregaard N. Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors. J Immunol 2003, 170:5583-5589.
124. Krane J.F., Gottlieb A.B., Carter D.M., Krueger J.G. The insulin-like growth factor I receptor is overexpressed in psoriatic epidermis, but is differentially regulated from the epidermal growth factor receptor. J Exp Med 1992, 175:1081-1090.
125. Elder J.T., Fisher G.J., Lindquist P.B., Bennett G.L., Pittelkow M.R., Coffey R.J., et al. Overexpression of transforming growth factor α in psoriatic epidermis. Science 1989, 243:811-814.
126. Gartner M.H., Benson J.D., Caldwell M.D. Insulin-like growth factors I and II expression in the healing wound. J Surg Res 1992, 52:389-394.
127. Rappolee D.A., Mark D., Banda M.J., Werb Z. Wound macrophages express TGF-α and other growth factors in vivo: analysis by mRNA phenotyping. Science 1988, 241:708-712.
128. Ong P.Y., Ohtake T., Brandt C., Strickland I., Boguniewicz M., Ganz T., et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002, 347:1151-1160.
129. Heilborn J.D., Frohm M., Kratz G., Weber G., Sørensen O., Borregaard N., et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol 1988, 120:379-389.
130. Abiko Y., Mitamura J., Nishimura M., Muramatsu T., Inoue T., Shimono M., et al. Pattern of expression of beta-defensins in oral squamous cell carcinoma. Cancer Lett 1999, 143:37-43.
131. Joly S., Compton L.M., Pujol C., Kurago Z.B., Guthmiller J.M. Loss of human β-defensin 1, 2, and 3 expression in oral squamous cell carcinoma. Oral Microbiol Immunol 2009, 24:353-360.
132. Abiko Y., Suraweera A.K., Nishimura M., Arakawa T., Takuma T., Mizoguchi I., et al. Differential expression of human beta-defensin 2 in keratinized and non- keratinized oral epithelial lesions; immunohistochemistry and in situ hybridization. Virchows Arch 2001, 438:248-253.
133. Hubert P., Herman L., Maillard C., Caberg J.-H., Nikkels A., Pierard G., et al. Defensins induce the recruitment of dendritic cells in cervical human papillomavirus-associated (pre)neoplastic lesions formed in vitro and transplanted in vivo. FASEB J 2007, 21:2765-2775.
134. Heilborn J.D., Frohm M., Chamorro C.I., Sandstedt B., Borregaard N., Tham E., et al. Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells. Int J Cancer 2005, 114:713-719.
135. Weber G, Chamorro C, Granath F, Liljegern A, Zreika S, Saidak Z, et al. Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer. Breast Cancer Res 2009;11:R6 []. doi:10.1186/bcr2221.
136. Coffelt S.B., Waterman R.S., Florez L., Höner zu Bentrup K., Zwezdaryk K.J., Tomchuck S.L., et al. Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. Int J Cancer 2008, 122:1030-1039.
137. Coffelt S.B., Tomchuck S.L., Zwezdaryk K.J., Danka E.S., Scandurro A.B. Leucine Leucine-37 uses formyl peptide receptor-like 1 to activate signal transduction pathways, stimulate oncogenic gene expression, and enhance the invasiveness of ovarian cancer cells. Mol Cancer Res 2009, 7:907-915.
138. von Haussen J., Koczulla R., Shaykhiev R., Herr C., Pinkenburg O., Reimer D., et al. The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer 2008, 59:12-23.
139. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415:389-395.
140. Marr A.K., Gooderham W.J., Hancock R.E. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opinion Pharma 2006, 6:468-472.
141. Giles F., Rodriguez R., Weisdorf D., Wingard J.R., Matin P.J., Fleming T.R., et al. A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leuk Res 2004, 28:559-565.
142. Paquette D.W., Waters G.S., Stefanidou V.L., Lawrence H.O., Friden P.M., O'Connor S.M., et al. Inhibition of experimental gingivitis in beagle dogs with topical salivary histatins. J Clin Periodontol 1997, 24:216-222.
143. Paquette D.W., Simpson D.M., Friden P., Braman V., Williams R.C. Safety and clinical effects of topical histatin gels in humans with experimental gingivitis. J Clin Periodontol 2002, 29:1051-1058.
144. Yoshinari M., Kato T., Matsuzaka K., Hayakawa T., Inoue T., Oda Y., et al. Adsorption behavior of antimicrobial peptide histatin 5 on PMMA. J Biomed Mater Res Part B Appl Biomater 2006, 77:47-54.
145. Overhage J., Campisano A., Bains M., Torfs E.C., Rehm B.H., Hancock R.E. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun 2008, 76:4176-4182.
146. Tsuda H., Sekine K., Fujita K., Ligo M. Cancer prevention by bovine lactoferrin and underlying mechanisms-a review of experimental and clinical studies. Biochem Cell Biol 2002, 80:131-136.
147. Jonasch E., Stadler W.M., Bukowski R.M., Hayes T.G., Varadhachary A., Malik R., et al. Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer 2008, 113:72-77.
148. Islam D., Bandholtz L., Nilsson J., Wigzell H., Christensson B., Agerberth B., et al. Downregulation of bactericidal peptides in enteric infections: a novel immune escape mechanism with bacterial DNA as a potential regulator. Nat Med 2001, 7:180-185.
149. Sandgren S., Wittrup S.A., Cheng F., Jönsson M., Eklund E., Busch S., et al. The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis. J Biol Chem 2004, 279:17951-17956.
150. Chuang C., Monie A., Wu A., Mao C., Hung C. Treatment with LL-37 peptide enhances the antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum Gene Ther 2009, 20:303-313.
151. Nijnik A., Hancock R.E.W. The role of cathelicidin LL-37 in immune defences and novel clinical applications. Curr Opin Hematol 2009, 16:41-47.